Skip to main navigation Skip to search Skip to main content

Drug discovery prospect from untapped species: Indications from approved natural product drugs

  • Feng Zhu
  • , Xiao Hua Ma
  • , Chu Qin
  • , Lin Tao
  • , Xin Liu
  • , Zhe Shi
  • , Cun Long Zhang
  • , Chun Yan Tan
  • , Yu Zong Chen
  • , Yu Yang Jiang
  • Tsinghua University
  • Chongqing University
  • National University of Singapore

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)

Abstract

Due to extensive bioprospecting efforts of the past and technology factors, there have been questions about drug discovery prospect from untapped species. We analyzed recent trends of approved drugs derived from previously untapped species, which show no sign of untapped drug-productive species being near extinction and suggest high probability of deriving new drugs from new species in existing drug-productive species families and clusters. Case histories of recently approved drugs reveal useful strategies for deriving new drugs from the scaffolds and pharmacophores of the natural product leads of these untapped species. New technologies such as cryptic gene-cluster exploration may generate novel natural products with highly anticipated potential impact on drug discovery.

Original languageEnglish
Article numbere39782
JournalPLoS ONE
Volume7
Issue number7
DOIs
Publication statusPublished - 11 Jul 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Drug discovery prospect from untapped species: Indications from approved natural product drugs'. Together they form a unique fingerprint.

Cite this